Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
about
Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast CancerThe Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.Progress with palbociclib in breast cancer: latest evidence and clinical considerations.Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.Inhibitors of cyclin-dependent kinases as cancer therapeutics.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis.4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.ABC4 Consensus: Assessment by a German Group of ExpertsUpdates on managing advanced breast cancer with palbociclib combination therapyClinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidenceCurrent Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
P2860
Q26738982-4BF08F87-B77F-4E0A-A2DE-79DE24826786Q37124719-E189A432-F84E-482C-8204-AC6405B14270Q37632170-9CB77BE4-9CDE-465D-A560-E6442A110D5BQ38662999-ADE2159E-086A-40B5-AFED-34C9F47C323EQ38709347-7EC39CA2-8CBC-486F-BD77-C472AFE98542Q39125016-460D586E-122F-4A3C-9AB1-DDF71C9F1A8FQ39172983-CA624721-BA8E-4DE8-AA97-976AC6A724CBQ39185424-8BD1D3AF-3569-4E7C-89AD-BA5A6ED058D3Q39294871-2297DADE-D113-4972-B8AF-4BF77C3D3853Q43281043-D37DAD93-D0FC-4FCE-B250-16ABB443DD8EQ47321026-63FF68E4-C6C6-4F6F-96C0-55CEECB4DE4DQ47393206-54686670-62F8-424B-9AAF-A4949E612591Q49885966-4805DC66-F88C-4518-B5F7-CE9E6ACE5178Q49970203-F139669A-4083-4C0E-AF8E-876716902DEDQ52707821-14325310-741E-40F8-B69F-A9E50A1EAD0FQ53738984-520A92BE-E5F1-420C-834D-D3B728C52A57Q54109356-54074C74-ABEA-4AF4-8A6D-AF4FA664E46BQ55346396-F22B4F83-B625-4D96-810C-24A05D970C75Q55365709-4755AB2A-21C3-4D5F-85B9-DA0033580333Q56968314-4A37703C-54AC-4F9D-9CF1-FF284FB11717Q57106487-F4907B5A-C1CB-4B71-901F-A0AA449B9AC4Q57107345-F8268C22-78B1-44CE-A376-C4512F55000EQ57108041-017D34A0-A353-46E8-A1C8-F46F88C4BBBF
P2860
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Quality of life with palbocicl ...... comes from the PALOMA-3 trial.
@en
type
label
Quality of life with palbocicl ...... comes from the PALOMA-3 trial.
@en
prefLabel
Quality of life with palbocicl ...... comes from the PALOMA-3 trial.
@en
P2093
P2860
P356
P1433
P1476
Quality of life with palbocicl ...... comes from the PALOMA-3 trial.
@en
P2093
C H Bartlett
H Bhattacharyya
K Puyana Theall
M Cristofanilli
P2860
P304
P356
10.1093/ANNONC/MDW139
P577
2016-03-30T00:00:00Z